Oliver Rolf Baumann Purchases 50,000 Shares of Veraxa Biotech (NASDAQ:VRXA) Stock

Posted by Geri Gentry on Sep 2nd, 2026

Veraxa Biotech Holding AG (NASDAQ:VRXA – Get Free Report) Director Oliver Rolf Baumann purchased 50,000 shares of Veraxa Biotech stock in a transaction dated Thursday, August 27th. The shares were purchased at an average cost of $1.50 per share, for a total transaction of $75,000.00. Following the transaction, the director owned 5,773,618 shares in the company, valued at approximately $8,660,427. This trade represents a 0.87% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Veraxa Biotech Price Performance

VRXA opened at $1.40 on Wednesday. Veraxa Biotech Holding AG has a one year low of $1.27 and a one year high of $27.36.

Wall Street Analyst Weigh In

Separately, Wall Street Zen upgraded Veraxa Biotech from a “sell” rating to a “hold” rating in a report on Monday.

Get Our Latest Analysis on Veraxa Biotech

Veraxa Biotech Company Profile

(Get Free Report)

Veraxa Biotech AG is a biotechnology company focused on developing targeted antibody-based medicines, with an emphasis on antibody-drug conjugates (ADCs). These therapies are designed to use antibodies to identify specific cells and deliver therapeutic agents more selectively.

The company’s work includes antibody discovery, therapeutic development and the design of ADC candidates that combine targeting antibodies with drug payloads. Its research is directed primarily toward potential treatments for cancer and other serious diseases, although specific development programs and product approvals may change as its pipeline advances.

Publicly available information about Veraxa Biotech’s corporate history, geographic operations and leadership is limited.